UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at intermediate-risk (IR) and high-risk (HR) of relapse. The goal is to achieve similar or better survival with chemotherapy cycles that are intensive but less likely to cause long-term complications. Patients will enroll on this trial at the end of their first induction cycle. The two cycles to be substituted are: * "Ida-FLA" (idarubicin+fludarabine/cytarabine) as Induction 2

Trial Details

NCT ID
NCT07059975
Phase
EARLY_PHASE1
Sponsor
Baylor College of Medicine
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Idarubicin Hydrochloride
  • Fludarabine
  • Cytarabine (Ara-C)
  • Venetoclax
  • Etoposide
  • Asparaginase Erwinia Chrysanthemi (recombinant)
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Age Patients ≥ 1 months old to ≤ 30 years old are eligible
  • Patients must be diagnosed with AML or myeloid sarcoma according to the 2022 WHO classification with or without extramedullary disease. Patients wi…
  • \- Diagnosis
  • ≥ 20% bone marrow blasts

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →